ASPIrin in Reducing Events in Dialysis ( ASPIRED )
Status:
Recruiting
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
People with kidney failure requiring dialysis have a much higher risk of developing
cardiovascular (CV) disease compared with the general population. A cardiac cause accounts
for 58% of all deaths in patients with end stage kidney disease (ESKD). At the same time,
this population has increased risks of clotting as well as bleeding episodes. While aspirin
is known to reduce cardiovascular complications in the general population, evidence to
support the use of aspirin in people with ESKD receiving dialysis therapy is currently
lacking. The ASPIrin to Reduce Event in Dialysis (ASPIRED) trial will test whether aspirin
use in dialysis patients safely improves outcomes compared with no aspirin use.